Deerland Invests in Capital Expenditures
Deerland Enzymes (Kennesaw, GA) recently invested in several capital expenditures at its Kennesaw headquarters. These expenditures included improved bulk blending capabilities for both large and small batch sizes, high speed encapsulation capabilities along with a broader spectrum of capsule sizes, a new tableting line to broaden manufacturing capabilities, automated bottling and labeling capacity, and automated inspection equipment.
Deerland Enzymes (Kennesaw, GA) recently invested in several capital expenditures at its Kennesaw headquarters. These expenditures included improved bulk blending capabilities for both large and small batch sizes, high speed encapsulation capabilities along with a broader spectrum of capsule sizes, a new tableting line to broaden manufacturing capabilities, automated bottling and labeling capacity, and automated inspection equipment.
“Deerland must evolve as our industry evolves. In doing so, it is vital that we continually invest in our business to meet or exceed the expectations of the customers who entrust us with their business,” said Scott Ravech, CEO.
“Deerland has recognized this and to support these needs we invested in additional manufacturing capabilities, which will help us be able to better partner with our customers from concept through to commercialization. This will be offered across the value chain to include product/formulation design, development and finished product.”
The Nutritional Outlook Podcast Episode 39: Nutritional Outlook's Ingredients to Watch in 2025
February 25th 2025In this episode, Nutritional Outlook interviews Scott Dicker, market insights director from market researcher SPINS, about ingredients and product categories nutraceutical and nutrition product manufacturers should watch in 2025.
